Back to Directory
research logo

Mosanna Therapeutics | Company Profile

9/24/2025

Contact Information

👤
Mosanna Therapeutics
🏢
Mosanna Therapeutics
📍
redwood city, california, united states

Industry & Market

Primary Industry
research
Location
Redwood City, California, United States

Company Metrics

👥Total Employees
3
⚙️Engineering
N/A
💼Sales Team
N/A
📈Marketing
N/A
📅Founded
2022
💰Revenue
N/A

Funding Information

Total Funding
$80.0M
Latest Stage
Series a

Headcount Distribution

Total Employees
3
Departments
19

By Department

Department Breakdown

Consulting
Finance
Operations
Accounting
Administrative
Arts And Design

Technology Stack

Analytics & Tracking

Google Tag Manager

Email & Communication

Outlook
Total: 12 technologies

Keywords & Focus Areas

biotechnology researchsmall molecule inhibitormos118airway dilationpressure-sensing nervespressure sensorsnegative pressure reflexpharmaceuticalspan-k+ channel inhibitorbiotechsleep disorder biotechbiotech startupdrug developmentsleep medicinemuscle tone activationmuscle activationbiological mechanismpharmaceutical innovationnon-invasive treatmentpressure-sensitive nerves+10 more
30 total keywords

Mosanna Therapeutics

Overview

Mosanna Therapeutics is a clinical-stage biotech company based in Basel, Switzerland, with an office in Redwood City, California. Founded in 2022, the company is dedicated to enhancing patient outcomes by developing innovative pharmaceutical treatments for obstructive sleep apnea (OSA). Their lead product candidate, MOS118, is a small molecule nasal spray currently in Phase 1 clinical trials. This therapy aims to restore the body's natural airway control during sleep, providing a drug-based alternative to traditional mechanical treatments like CPAP devices.

Employing a precision medicine approach, the company collaborates with specialized contract research organizations to select and develop innovative medicines. Mosanna Therapeutics focuses on delivering an effective and well-tolerated nasal spray for patients suffering from Metabolic Obstructive Sleep Apnea, a specific subtype of OSA. With over $80 million in funding from notable investors, the company benefits from a leadership team with extensive experience in pharmaceutical development and regulatory affairs.

Basic Information

Industry research
Founded 2022
Revenue 80M
Headquarters Redwood City, California, United States
Latest Funding Stage Series A

Contact Details

Key Focus Areas & Initiatives

  • Biotechnology research
  • Small molecule inhibitor
  • MOS118 development
  • Airway dilation therapies
  • Pressure-sensing nerve studies
  • Negative pressure reflex investigation
  • Pharmaceutical innovation
  • Pan-K+ channel inhibitor research
  • Biotech advancement
  • Sleep disorder treatment
  • Drug development and formulation
  • Muscle tone activation research
  • Non-invasive therapeutic approaches
  • Metabolic Obstructive Sleep Apnea focus
  • Neurobiology and neurophysiological treatments
  • Clinical development in sleep medicine
  • Drug delivery innovation
  • Pharmaceutical nasal spray therapy
  • Leadership in biotech startup ecosystem
  • B2C & D2C research applications

Technologies Used

  • Apache
  • Circle
  • Domo
  • Google Font API
  • Google Maps
  • Google Tag Manager
  • KNIME
  • Mobile Friendly
  • Outlook
  • PEO
  • Sisense
  • WordPress.org

Need more information?

Find decision makers, more insights and contact information about this company on Bitscale

Try Bitscale Now

Schedule your demo now!

See how BitScale can supercharge your outbound sales in a 30-minute demo

SayData

© 2025 Bitscale. Featherflow Technology Pvt Ltd

LinkedInTwitterInstagramYouTube